Kim Abbenhaus
About Kim Abbenhaus
Kim Abbenhaus serves as the Vice President and General Manager for DACH at Aimmune Therapeutics, a position she has held since 2019. She has previously held leadership roles at Novartis Pharma GmbH and ALLERGIKA Pharma GmbH.
Work at Aimmune Therapeutics
Kim Abbenhaus has served as Vice President and General Manager for the DACH region at Aimmune Therapeutics since 2019. In this role, she oversees operations and strategic initiatives within the German-speaking countries of Germany, Austria, and Switzerland. Her leadership contributes to the company's mission of developing treatments for food allergies, particularly in the context of innovative therapies.
Previous Experience at Novartis Pharma GmbH
Prior to her current position, Kim Abbenhaus worked at Novartis Pharma GmbH in various roles. She was the Business Franchise Head for Allergy and Respiratory from 2009 to 2011, where she managed product portfolios and marketing strategies. Following that, she served as Franchise Head for Critical Care from 2012 to 2014, focusing on critical care products and market development.
Role at ALLERGIKA Pharma GmbH
Before joining Aimmune Therapeutics, Kim Abbenhaus was the Managing Director for Germany at ALLERGIKA Pharma GmbH from 2018 to 2019. In this capacity, she was responsible for the overall management and strategic direction of the company in the German market, contributing to its growth and operational success.
Career Timeline
Kim Abbenhaus has a diverse career spanning over a decade in the pharmaceutical industry. Her professional journey includes significant roles at Novartis Pharma GmbH and ALLERGIKA Pharma GmbH, with a focus on allergy, respiratory, and critical care sectors. She has accumulated extensive experience in management and strategic planning within these specialized areas.